Modified Ferriman-Gallwey Score Calculator- Free Hirsutism Assessment and Scoring Tool

About This Modified Ferriman-Gallwey Score Calculator

This Modified Ferriman-Gallwey (mFG) Score Calculator is designed for women concerned about excess body hair growth who want to assess their hirsutism severity using the internationally recognized clinical scoring system. The tool evaluates terminal hair growth across nine androgen-sensitive body areas (upper lip, chin, chest, upper back, lower back, upper abdomen, lower abdomen, upper arm, and thigh), each scored from 0 to 4, producing a total hirsutism score ranging from 0 to 36.

The calculator follows the modified scoring methodology introduced by Hatch, Rosenfield, Kim, and Tredway in 1981, which refined the original 1961 Ferriman-Gallwey system by excluding the forearms and lower legs. It incorporates severity classification thresholds endorsed by the Endocrine Society Clinical Practice Guideline (2018) and the Androgen Excess and PCOS Society consensus statement (2012), classifying scores into normal (0-7), mild hirsutism (8-15), moderate hirsutism (16-25), and severe hirsutism (26-36) categories.

The interactive radar chart visualization reveals your score distribution pattern across all nine body regions, helping identify which areas contribute most to your total score. The ethnicity-specific threshold reference table accounts for the significant variation in baseline hair growth across populations, and the clinical action recommendations provide guidance on when to seek professional medical evaluation, hormonal testing, and treatment. This tool is intended for self-screening and treatment monitoring, not as a substitute for clinical assessment by a qualified healthcare professional.

Modified Ferriman-Gallwey Score Calculator – Complete Guide to Hirsutism Assessment, Scoring, and Clinical Interpretation

Hirsutism, defined as excessive terminal hair growth in a male-pattern distribution in women, affects approximately 5 to 15 percent of the female population worldwide. It is one of the most common reasons for dermatology and endocrinology consultations and can cause significant psychological distress. The Modified Ferriman-Gallwey (mFG) score is the gold standard clinical tool for evaluating and quantifying the severity of hirsutism. Developed originally by D. Ferriman and J.D. Gallwey in 1961 and later refined by Hatch and colleagues in 1981, this visual scoring system provides a standardized, reproducible method for clinicians to assess terminal hair growth across nine androgen-sensitive body regions. Understanding how this scoring system works empowers both healthcare providers and patients to make more informed decisions about diagnosis, treatment monitoring, and the need for further investigation into underlying hormonal conditions.

What Is Hirsutism and Why Does It Matter?

Hirsutism refers specifically to the growth of coarse, dark terminal hairs in areas where women typically have only fine vellus (peach fuzz) hair. These areas include the upper lip, chin, chest, back, abdomen, and thighs. It is important to distinguish hirsutism from hypertrichosis, which is a generalized increase in hair growth not limited to androgen-sensitive areas and not necessarily driven by hormonal factors. Hirsutism is almost always linked to increased androgen activity, whether from elevated circulating androgen levels or increased sensitivity of hair follicles to normal androgen levels.

The clinical significance of hirsutism extends beyond cosmetic concerns. It frequently serves as an external marker of underlying endocrine disorders, most commonly polycystic ovary syndrome (PCOS), which accounts for approximately 70 to 80 percent of all hirsutism cases. Other potential causes include non-classic congenital adrenal hyperplasia, Cushing syndrome, androgen-secreting tumors of the ovaries or adrenal glands, certain medications (such as anabolic steroids, danazol, or some hormonal therapies), and idiopathic hirsutism where no identifiable hormonal abnormality can be found despite clinical symptoms. Recognizing and quantifying hirsutism through standardized tools like the Ferriman-Gallwey score is essential for guiding appropriate diagnostic workup and treatment decisions.

History and Development of the Ferriman-Gallwey Score

The original Ferriman-Gallwey scoring system was published in the Journal of Clinical Endocrinology and Metabolism in 1961. D. Ferriman and J.D. Gallwey designed the system to create a reproducible, objective clinical tool for assessing body hair growth in women. Their original method evaluated terminal hair density at 11 body sites: the upper lip, chin, chest, upper abdomen, lower abdomen, upper arms, forearms, thighs, lower legs, upper back, and lower back. Each site was scored on a scale from 0 (no terminal hair) to 4 (extensive hair growth equivalent to male-pattern density), yielding a maximum possible score of 44.

In 1981, Hatch, Rosenfield, Kim, and Tredway published a modification that simplified the scoring by eliminating two body areas, the forearms and lower legs, as terminal hair growth in these regions was found to correlate poorly with androgen excess. This Modified Ferriman-Gallwey (mFG) score evaluates only nine body areas, producing a maximum score of 36. The mFG system became the standard adopted by major endocrine and dermatological societies worldwide, including the Endocrine Society and the Androgen Excess and PCOS Society. In 2001, Goodman and colleagues proposed a further expansion to 19 body areas, but this extended version has seen limited adoption in routine clinical practice due to its complexity and the added patient discomfort of more extensive examination.

The Nine Body Areas Assessed in the Modified Ferriman-Gallwey Score

The Modified Ferriman-Gallwey scoring system evaluates terminal hair growth at nine specific androgen-sensitive body regions. Each area is assessed independently using a standardized visual scale from 0 to 4. Understanding the scoring criteria for each region is critical for accurate and reproducible assessment.

1. Upper Lip: Score 0 indicates no terminal hair growth above the lip. Score 1 represents a few scattered terminal hairs at the outer margins of the lip. Score 2 indicates a small but noticeable mustache at the outer margins. Score 3 shows a mustache extending halfway from the outer margin toward the midline. Score 4 indicates a full mustache extending to the midline of the upper lip.

2. Chin: Score 0 indicates no terminal hair on the chin. Score 1 represents a few scattered terminal hairs. Score 2 shows scattered hairs with small concentrations. Score 3 indicates complete light coverage of the chin area. Score 4 represents heavy, dense coverage similar to a male beard pattern.

3. Chest: Score 0 indicates no terminal hair. Score 1 represents a few circumareolar (around the nipple) hairs. Score 2 shows circumareolar hairs plus hair on the midline between the breasts. Score 3 indicates fusion of the circumareolar and midline areas with three-quarter coverage. Score 4 represents complete coverage of the chest area.

4. Upper Back: Score 0 indicates no terminal hair. Score 1 represents a few scattered terminal hairs. Score 2 shows more hairs that remain scattered. Score 3 indicates complete light coverage of the upper back. Score 4 represents thick, dense coverage of the upper back region.

5. Lower Back: Score 0 indicates no terminal hair. Score 1 represents a sacral tuft of hair (small patch over the sacrum). Score 2 shows the sacral tuft extending laterally. Score 3 indicates three-quarter coverage of the lower back. Score 4 represents complete coverage of the lower back.

6. Upper Abdomen: Score 0 indicates no terminal hair. Score 1 represents a few scattered midline hairs. Score 2 shows more midline hairs forming a line. Score 3 indicates half coverage of the upper abdomen. Score 4 represents full coverage of the upper abdomen region.

7. Lower Abdomen: Score 0 indicates no terminal hair. Score 1 represents a few midline hairs below the navel. Score 2 shows a midline streak of hair. Score 3 indicates a midline band of hair. Score 4 represents an inverted V-shaped pattern (male-pattern) covering the lower abdomen.

8. Upper Arm: Score 0 indicates no terminal hair. Score 1 represents sparse hair growth affecting less than a quarter of the limb surface. Score 2 shows more hair growth but still incomplete coverage. Score 3 indicates complete light coverage. Score 4 represents complete dense coverage of the upper arm.

9. Thigh: Score 0 indicates no terminal hair. Score 1 represents sparse hair growth. Score 2 shows more hair growth but still incomplete coverage. Score 3 indicates complete light coverage. Score 4 represents complete dense coverage of the thigh.

Interpreting the Total Modified Ferriman-Gallwey Score

The total mFG score provides a quantitative measure of hirsutism severity that guides clinical decision-making. Interpretation requires consideration of the patient’s ethnic background, as baseline hair growth patterns vary significantly across populations. The most widely cited threshold of 8 or higher was established in predominantly Caucasian populations.

A total score of 0 to 7 is generally considered within the normal range for Caucasian women, representing typical variation in body hair distribution. Locally excessive hair growth in one or two areas with a total score below 8 is a common normal variant and does not typically warrant concern for underlying endocrine pathology.

A total score of 8 to 15 is classified as mild hirsutism. This range suggests clinically significant excess terminal hair growth that may indicate androgen excess. Patients in this range should be evaluated for underlying causes, particularly if accompanied by other signs such as irregular menstrual cycles, acne, or unexplained weight gain.

A total score of 16 to 25 is classified as moderate hirsutism. This degree of excess hair growth strongly suggests an underlying hormonal disturbance and warrants comprehensive endocrine evaluation including blood tests for androgens, assessment for PCOS, and potentially imaging studies.

A total score of 26 to 36 is classified as severe hirsutism. Scores in this range are uncommon and may indicate a more serious underlying condition such as an androgen-secreting tumor or severe adrenal enzyme deficiency. Urgent referral to an endocrinologist is recommended for scores in this range.

Ethnic and Racial Variations in Scoring Thresholds

One of the most important considerations when interpreting the Ferriman-Gallwey score is the substantial variation in terminal hair growth across ethnic and racial groups. The standard threshold of 8 was established in Caucasian populations and may not be universally applicable. The local concentration of the enzyme 5-alpha-reductase in the skin, which converts testosterone to the more potent dihydrotestosterone, varies significantly by ethnicity. This enzyme activity directly influences the pattern and density of terminal hair growth.

Women of Mediterranean, Middle Eastern, and South Asian descent tend to have naturally denser body hair and may require a higher threshold (scores of 9 to 10 or higher) to accurately diagnose clinically significant hirsutism. Conversely, women of East Asian and Native American descent typically have less body hair, and studies in these populations have suggested that lower thresholds may be more appropriate. Research among Filipino women established a cut-off of 7 or higher. A study in a South Indian population found that a score of just 5 or more was sufficient for diagnosis. Chinese women in one study demonstrated that an mFG score of 5 or above was diagnostic when using a simplified scoring method.

These ethnic variations underscore the importance of interpreting the mFG score within the context of the individual patient’s ethnic background and not applying a single universal threshold. Healthcare providers should be aware of population-specific reference ranges and consider the patient’s family history of hair growth patterns when making clinical interpretations.

Clinical Applications of the Ferriman-Gallwey Score

The Modified Ferriman-Gallwey score serves multiple clinical purposes beyond initial diagnosis. Its primary applications include screening and initial assessment of hirsutism severity, guiding the choice and intensity of treatment, monitoring treatment response over time, research standardization for clinical trials and epidemiological studies, and patient self-assessment for tracking changes between clinic visits.

In the diagnostic workup, the mFG score helps clinicians determine which patients need further hormonal testing. The Endocrine Society Clinical Practice Guideline on hirsutism (2018) recommends measuring serum androgen levels, particularly total and free testosterone, in all women with a clinical diagnosis of hirsutism based on the mFG score. For patients with moderate to severe hirsutism, additional testing may include dehydroepiandrosterone sulfate (DHEA-S), 17-hydroxyprogesterone, and cortisol levels to evaluate for adrenal causes.

For treatment monitoring, serial mFG scoring provides an objective measure of therapeutic response. Treatment effects on hirsutism typically take several months to become apparent due to the hair growth cycle, so repeat assessments at 6 to 12 month intervals are recommended. A clinically meaningful improvement is generally considered to be a reduction of 3 or more points in the total mFG score.

Common Causes of Hirsutism Evaluated with the Ferriman-Gallwey Score

When a patient presents with an elevated mFG score, the clinical evaluation focuses on identifying the underlying cause. Polycystic ovary syndrome (PCOS) is by far the most common etiology, accounting for approximately 70 to 80 percent of cases. PCOS is characterized by a combination of hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology on ultrasound. Women with PCOS typically present with mild to moderate mFG scores (8-20) along with irregular menstrual cycles and often acne or scalp hair thinning.

Idiopathic hirsutism, the second most common diagnosis, accounts for approximately 5 to 20 percent of cases. These patients have elevated mFG scores but normal circulating androgen levels and regular ovulatory cycles. The condition is thought to result from increased peripheral 5-alpha-reductase activity or increased androgen receptor sensitivity in the skin.

Non-classic congenital adrenal hyperplasia (NCAH) accounts for approximately 1 to 8 percent of hirsutism cases, depending on the population studied. This condition involves a partial deficiency of the enzyme 21-hydroxylase, leading to excess adrenal androgen production. It is diagnosed by measuring an early-morning 17-hydroxyprogesterone level. Cushing syndrome, androgen-secreting tumors of the ovaries or adrenal glands, thyroid disorders, and medication-induced hirsutism account for the remaining cases. Rapid onset of severe hirsutism (high mFG scores developing over weeks to months), particularly when accompanied by virilization signs such as deepening voice, increased muscle mass, clitoromegaly, or male-pattern balding, raises strong suspicion for an androgen-secreting tumor and warrants urgent evaluation.

Limitations of the Ferriman-Gallwey Scoring System

While the mFG score remains the most widely used clinical tool for hirsutism assessment, it has several recognized limitations that clinicians and patients should understand. The most significant limitation is subjectivity. The scoring relies entirely on visual assessment by the examiner, introducing the possibility of inter-observer and intra-observer variability. Studies have documented kappa coefficients ranging from 0.585 (upper lip, lowest agreement) to 0.847 (upper back, highest agreement) between two trained physicians scoring the same patients simultaneously. This variability highlights the importance of having the same clinician perform serial assessments when monitoring treatment response.

The score does not account for hair color or texture variations. A woman with very dark, coarse terminal hairs may score the same as a woman with lighter, finer terminal hairs in the same distribution, despite the former potentially having a more noticeable cosmetic impact. Similarly, the mFG score does not capture the psychological impact of hirsutism, which can be substantial and may not correlate directly with the severity of the score.

Patient self-scoring has been explored as an alternative to clinician assessment, particularly for remote monitoring. However, studies comparing patient self-scores with clinician scores have shown significant discrepancies, with patients often underestimating or inconsistently scoring their hair growth. Self-scoring may still be useful for tracking relative changes over time when performed consistently by the same individual.

Finally, the examination requires assessment of sensitive body areas including the chest, abdomen, and thighs, which can be uncomfortable or embarrassing for patients. This has led researchers to investigate whether scoring a subset of body areas (such as the chin, upper lip, and lower abdomen alone) might reliably predict the total score. Research has shown that the combination of chin, upper abdomen, and lower abdomen scores is the strongest predictor of total body hirsutism.

The Ferriman-Gallwey Score and PCOS Diagnosis

The Modified Ferriman-Gallwey score plays a central role in the diagnostic criteria for polycystic ovary syndrome. Under the widely used Rotterdam criteria, PCOS is diagnosed when at least two of three features are present: oligo-ovulation or anovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology on ultrasound. Clinical hyperandrogenism, as assessed by the mFG score, is one of the primary diagnostic markers. An mFG score of 8 or above satisfies the clinical hyperandrogenism criterion in Caucasian women.

The Androgen Excess and PCOS Society (AE-PCOS Society) has published consensus statements emphasizing that hirsutism assessment using the mFG score should be a standard component of PCOS evaluation. Their 2012 consensus statement recommends that the mFG score be performed as part of the initial clinical assessment and at regular follow-up visits to monitor treatment efficacy. The International Evidence-based Guideline for the Assessment and Management of PCOS (2023) similarly endorses the mFG score as the primary clinical tool for hirsutism assessment.

It is worth noting that not all women with PCOS present with hirsutism. The prevalence of hirsutism among women with PCOS varies by ethnicity, ranging from approximately 60 percent in Caucasian women to lower rates in East Asian populations. Therefore, the absence of an elevated mFG score does not rule out PCOS, and the full diagnostic criteria should always be considered.

Treatment Options Guided by Ferriman-Gallwey Score Severity

The severity of hirsutism as quantified by the mFG score helps guide treatment selection. For mild hirsutism (mFG 8-15), initial management often includes cosmetic measures such as shaving, waxing, threading, depilatory creams, or topical eflornithine cream, along with lifestyle modifications including weight management for overweight patients. Pharmacological therapy may be initiated with oral contraceptive pills containing anti-androgenic progestins.

For moderate hirsutism (mFG 16-25), combination therapy is typically recommended. This may include oral contraceptive pills combined with an anti-androgen medication such as spironolactone, cyproterone acetate, or finasteride, depending on the clinical context and regional prescribing practices. Laser hair removal or intense pulsed light therapy may also be offered as a longer-term hair reduction strategy.

For severe hirsutism (mFG 26-36), aggressive pharmacological treatment is warranted alongside evaluation and treatment of any identified underlying cause. High-dose anti-androgen therapy, combination hormonal treatment, and professional hair removal procedures may all be components of the management plan. Referral to specialized endocrinology services is strongly recommended for severe cases.

Regardless of severity, treatment response should be monitored with repeat mFG scoring at 6 to 12 month intervals. It is important to counsel patients that significant improvement takes time due to the hair growth cycle, and that most pharmacological treatments require at least 6 months before measurable reduction in hair growth becomes apparent.

Self-Assessment Considerations and When to Seek Medical Advice

While the Ferriman-Gallwey score is designed as a clinician-administered tool, self-assessment can provide a useful starting point for women who are concerned about excess hair growth. A self-assessment can help identify whether the pattern and extent of hair growth warrants a medical consultation. However, it is important to recognize that self-scoring has significant limitations compared to professional assessment.

Women should consider seeking medical evaluation if they notice new terminal hair growth in androgen-sensitive areas (particularly the chin, upper lip, chest, or lower abdomen), if existing hair growth appears to be increasing in density or spreading to new areas, if excess hair growth is accompanied by irregular or absent menstrual periods, if there is concurrent development of acne or scalp hair thinning, if there is unexplained weight gain particularly around the midsection, or if hair growth develops rapidly over weeks to months rather than gradually.

Any woman who calculates a self-assessment mFG score of 8 or higher should discuss their findings with a healthcare provider. Even women with scores below 8 who are distressed by their hair growth should feel comfortable seeking medical advice, as the psychological impact of hirsutism is valid regardless of the numerical score.

Validation Across Diverse Populations

The Modified Ferriman-Gallwey score has been studied extensively across diverse populations worldwide, with varying results regarding optimal diagnostic thresholds. These studies highlight both the universal applicability of the scoring method and the need for population-specific interpretation.

In North American and European populations, the standard threshold of 8 has been validated across multiple large studies and is endorsed by the Endocrine Society. In Turkish women, who are primarily Caucasian, an mFG score of 8 or above was confirmed as diagnostic for hirsutism. Studies in Latin American populations have similarly supported the threshold of 8 for Hispanic women of mixed ethnic backgrounds.

In East Asian populations, research has consistently demonstrated lower baseline hair growth. A study of Filipino women established a cut-off of 7, while Chinese studies have suggested thresholds as low as 5 using simplified scoring methods. Japanese and Korean populations similarly tend to have lower normal ranges, suggesting that thresholds of 5 to 7 may be more appropriate for East Asian women.

In South Asian populations, results have been more variable. Some studies in Indian women have suggested lower thresholds (5 or above), while others have found the standard threshold of 8 to be appropriate. This variability likely reflects the significant ethnic diversity within South Asian populations. Middle Eastern and North African populations generally demonstrate higher baseline hair growth, and some researchers have suggested thresholds of 9 to 10 for these groups.

These population-specific data underscore the critical importance of ethnicity-specific normative ranges in the clinical application of the mFG score. Healthcare providers worldwide should be aware of the most relevant threshold for their patient populations rather than applying a single universal cut-off.

Regional Variations and Alternative Scoring Systems

While the Modified Ferriman-Gallwey score remains the most widely used tool globally, several alternative and complementary assessment methods have been developed. The 2001 Goodman modification expanded the scoring to 19 body areas, adding the sideburns, neck, buttocks, inguinal area, perianal area, forearm, leg, foot, toes, and fingers. While more comprehensive, this expanded version is rarely used in routine clinical practice due to the time required and additional patient discomfort.

Research has explored simplified versions of the mFG score that might be equally effective for screening purposes. A major study of 1,951 patients demonstrated that scoring only three body areas (chin, upper abdomen, and lower abdomen) could accurately predict the total mFG score and distinguish hirsute from non-hirsute women with 86 percent accuracy, 75 percent sensitivity, and 97 percent specificity. This simplified approach is particularly valuable in settings where time or privacy constraints limit the ability to perform a full nine-area assessment.

Photographic methods, computer-assisted hair measurement systems, and dermoscopy-based assessments have also been explored as alternatives or supplements to visual scoring. These technical approaches offer potentially greater objectivity but require specialized equipment and are not widely available in routine clinical settings. For most clinical purposes, the standard nine-area mFG score remains the recommended first-line assessment tool for hirsutism evaluation.

The Role of Laboratory Testing Alongside the Ferriman-Gallwey Score

The mFG score provides a clinical assessment of hirsutism but does not directly measure androgen levels. Biochemical testing is an essential complement to clinical scoring. The Endocrine Society recommends measuring total and free testosterone levels in all women with an elevated mFG score. Free testosterone, calculated using total testosterone and sex hormone-binding globulin (SHBG), is the most sensitive biochemical marker of hyperandrogenism.

Additional laboratory tests that may be indicated based on clinical presentation include 17-hydroxyprogesterone (to screen for non-classic congenital adrenal hyperplasia, ideally measured in the early morning follicular phase), DHEA-S (to evaluate adrenal androgen production), thyroid function tests, prolactin levels, and fasting glucose or insulin levels (given the strong association between PCOS and insulin resistance). In cases of severe or rapidly progressive hirsutism, imaging studies such as ovarian and adrenal ultrasound or CT scanning may be necessary to evaluate for androgen-secreting tumors.

It is important to note that approximately 40 to 50 percent of women with mild hirsutism have normal androgen levels, a condition termed idiopathic hirsutism. The mFG score remains clinically valid in these cases because the clinical manifestation (excess hair growth) exists regardless of whether a biochemical abnormality can be identified. Treatment decisions for idiopathic hirsutism are guided by symptom severity as assessed by the mFG score and the patient’s degree of distress.

Hair Growth Biology and the Ferriman-Gallwey Score

Understanding the biology of hair growth helps contextualize the Ferriman-Gallwey scoring system. Human hair exists in three types: lanugo (fine, soft hair present in fetuses), vellus hair (short, fine, lightly pigmented peach fuzz), and terminal hair (long, coarse, pigmented hair such as that on the scalp, eyebrows, and eyelashes). The conversion of vellus hair to terminal hair in androgen-sensitive body areas is the fundamental process underlying hirsutism.

Hair growth follows a cyclical pattern with three phases: anagen (active growth phase, lasting 2-6 years for scalp hair but only months for body hair), catagen (regression phase, lasting 2-3 weeks), and telogen (resting phase, lasting 2-3 months). At any given time, body hairs are in different phases of this cycle, which explains why treatment effects on hirsutism take several months to become apparent, as ongoing treatment must affect new hair entering the anagen phase.

Androgens, particularly dihydrotestosterone (DHT) formed from testosterone by the enzyme 5-alpha-reductase in the skin, stimulate the conversion of vellus to terminal hair follicles in androgen-sensitive areas. The density and activity of 5-alpha-reductase varies across body regions and across ethnic groups, explaining both the pattern of hair growth assessed by the mFG score and the ethnic variations in scoring thresholds. Paradoxically, androgens have the opposite effect on scalp hair follicles, promoting miniaturization and eventual loss, which is why androgenetic alopecia (male-pattern baldness) can co-occur with hirsutism.

Using the Ferriman-Gallwey Calculator for Self-Assessment

This calculator tool allows you to perform a self-assessment using the Modified Ferriman-Gallwey scoring system. For each of the nine body areas, you will assign a score from 0 to 4 based on the descriptions provided. The calculator will automatically sum your individual area scores to produce a total mFG score and provide an interpretation based on established clinical thresholds.

To use the calculator effectively, examine each body area in good lighting, ideally natural daylight. Focus on terminal hairs only, which are the coarse, dark, long hairs. Ignore fine, light vellus hairs. Score each area independently based on the descriptions for that specific region. Be as honest and consistent as possible in your assessments. If you are unsure between two scores for a given area, select the lower score to avoid overestimation.

Remember that self-assessment has known limitations compared to professional clinician scoring. Studies have shown that patients may score inconsistently or differently from trained clinicians. The self-assessment score should be viewed as a screening tool and a starting point for conversation with your healthcare provider, not as a definitive diagnosis. If your score is 8 or higher, or if you are concerned about your hair growth regardless of your score, consult a healthcare professional for a thorough evaluation.

Frequently Asked Questions

Conclusion

The Modified Ferriman-Gallwey score remains the cornerstone of hirsutism assessment in clinical practice worldwide. Despite being developed over six decades ago, its simplicity, reproducibility, and clinical utility have ensured its continued relevance. The scoring system provides a standardized language for clinicians and patients to discuss hirsutism severity, guide diagnostic workup, select appropriate treatments, and monitor therapeutic response over time. Understanding the scoring methodology, interpretation thresholds, and limitations of the mFG system empowers patients to participate actively in their own healthcare decisions. While self-assessment cannot replace professional clinical evaluation, tools like this calculator can serve as valuable screening aids and conversation starters between patients and their healthcare providers. If you are concerned about excess hair growth, do not hesitate to discuss your findings with a qualified healthcare professional who can provide personalized evaluation and treatment recommendations.